Pasireotide Explained

Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States[1] and the European Union[2] [3] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[4] [5] [6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness.[7] [8]

Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012[9] and by the U.S. Food and Drug Administration (FDA) in December 2012.[10]

Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014,[11] and had been approved for this indication by the EMA in September 2014.[12]

Notes and References

  1. Web site: Drug Approval Package: Signifor (pasireotide) Injection NDA #200677 . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 13 May 2020.
  2. Web site: Signifor EPAR . European Medicines Agency (EMA) . 17 September 2018 . 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. Web site: Summary of Product Characteristics: Signifor . European Medicines Agency . 27 September 2016 . 14 June 2018 . https://web.archive.org/web/20180614200149/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf . dead .
  4. Web site: Pasireotide Orphan Drug Designation and Approval . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 13 May 2020.
  5. Web site: EU/3/09/671 . European Medicines Agency . 17 September 2018 . 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. Mancini T, Porcelli T, Giustina A . Treatment of Cushing disease: overview and recent findings . Therapeutics and Clinical Risk Management . 6 . 505–16 . October 2010 . 21063461 . 2963160 . 10.2147/TCRM.S12952 . free .
  7. Web site: Signifor- pasireotide injection . DailyMed . 15 January 2020 . 13 May 2020.
  8. Web site: Signifor LAR- pasireotide kit . DailyMed . 17 December 2019 . 13 May 2020.
  9. Web site: EMEA Approval for Pasireotide . 26 January 2014 . 4 February 2014 . https://web.archive.org/web/20140204042347/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Fhuman%2Forphans%2F2009%2F11%2Fhuman_orphan_000677.jsp . dead .
  10. Web site: FDA Approves Pasireotide for Cushing's Disease.
  11. Web site: Signifor LAR (pasireotide) for injectable suspension . U.S. Food and Drug Administration (FDA) . 1 March 2016 . 13 May 2020.
  12. Web site: Tucker . Miriam E . vanc . FDA Approves Pasireotide for Treating Acromegaly . Medscape . 17 December 2014 . 2 August 2015 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pasireotide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.